Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

by Medical Finance
in Coronavirus
Study: Broad SARS-CoV-2 spike-specific CD4+ T-cell response preserves recognition of variants of concern. Image Credit: Naeblys/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the Research Square* preprint server, and currently under consideration at a Nature Portfolio Journal, researchers characterized over 100 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific CD4+ T-cell epitopes.

Study: Broad SARS-CoV-2 spike-specific CD4+ T-cell response preserves recognition of variants of concern. Image Credit: Naeblys/Shutterstock
Study: Broad SARS-CoV-2 spike-specific CD4+ T-cell response preserves recognition of variants of concern. Image Credit: Naeblys/Shutterstock

Additionally, they mapped 21 CD4+ T cell epitopes to three SARS-CoV-2 proteins – spike (S), nucleocapsid (N), and membrane (M).

Background

CD4+ T-cells, a key component of adaptive immunity, generate a more durable response to viral infections, including SARS-CoV-2 infections. They also dominate memory T-cell responses to SARS-CoV-2 S in vaccinated and previously infected individuals.

However, assay-based studies have mapped only a few SARS-CoV-2 CD4+ T cell epitopes using high concentrations of peptides, and in silico human leukocyte antigen (HLA) binding algorithms have helped infer HLA restrictions in the epitopes. The following three aspects of SARS-CoV-2-specific CD4+ T-cells are unknown –

  1. the specificity of CD4+ T-cell responses at the epitope level,
  2. the extent to which these responses cross-react with other human coronaviruses (HCoVs), and
  3. CD4+ T-cell sensitivity to mutations in SARS-CoV-2 variants of concern (VOC).

About the study

In the current study, researchers collected blood samples from 20 healthcare workers (HCW) infected with SARS-CoV-2 wild-type (wt) D614G strain during the first wave of the coronavirus disease 2019 (COVID-19) pandemic in the United Kingdom (UK) in 2020. Likewise, they gathered samples from the control group of individuals who were confirmed to be seronegative for SARS-CoV-2.

The researchers isolated peripheral blood mononuclear cells (PBMCs) and plasma from donor blood samples and generated CD8-depleted PBMCs using anti-CD8 Dynabeads to >94%, as measured by flow cytometry. They performed ex vivo interferon-gamma (IFNg) Elispot assays on whole or CD8-depleted PBMCs to quantify antigen-specific responses, expressed as spot-forming cells (sfc) per 106 cells.

Furthermore, the team used an enzyme-linked immunosorbent assay (ELISA) to test IFNg release into the supernatant medium used for polyclonal T cell lines, and a multiplex serology assay to quantify the immunoglobulin G (IgG) antibody titers against SARS-CoV-2 S and N and HCoV family S proteins.

The researchers also assessed SARS-CoV-2 S-specific CD4+ T-cell clones against SARS, Middle Eastern Respiratory Syndrome coronavirus (MERS), human coronavirus (HKU1), and OC43 S1 or S2 pepmixes. Wherever possible, they tested multiple T-cell clones per epitope.

Lastly, the team assessed the recognition of SARS-CoV-2 VOCs at the epitope level, in particular for VOCs – Alpha (B.1.1.7), Gamma (P1), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529).

Study findings

CD4+ T cell responses, to a control pepmix of HLA class I-restricted epitopes, decreased significantly in CD8-depleted PBMCs, whereas, these responses increased to S (S1 and S2), M, and N proteins, thus, indicating a predominance of CD4+ T-cell memory.

The authors detected weak responses to three SARS-CoV-2 proteins in CD8-depleted PBMCs from 14 control group individuals, with no S or N-specific antibody responses, most likely representing cross-reactive T cells primed by prior exposure to HCoVs.

Upon testing against individual 20-mer peptides, the authors noted that the S-specific polyclonal CD4+ T-cell line displayed responses against several peptides, including the receptor-binding domain (RBD), S1, and S2 regions. Similarly, it broadly responded to SARS-CoV-2 M and N proteins, indicating that SARS-CoV-2 induced a broad CD4+ T-cell response.

The researchers isolated CD4+ T-cell clones specific for 21 epitopes, 17 S, 2 N, and 2 M epitopes, from six study participants with varying HLA-II types. T-cell clones specific to 17 epitopes within S recognized autologous lymphoblastoid cell lines (LCL) pre-exposed to low concentrations of purified S protein, demonstrating that the major histocompatibility complex (MHC) II processing pathway generated all the 21 epitopes efficiently.

The authors also observed that SARS-CoV-2 infection and vaccination equally induced broad CD4+ T-cell responses to shared epitopes, and the HLA-II genotype was a key determinant of these responses.

All T cell clones showed similar levels of recognition against S1 or S2 SARS-CoV-2 pepmix and T cell clone’s-related epitope peptide. However, they detected no cross-reactivity against any other HCoV within the more divergent S1 region. Overall, S epitope-specific CD4+ T-cells isolated following SARS-CoV-2 infection could recognize highly homologous epitopes within the S2 region of SARS- but did not cross-react with MERS- or distant HCoVs, such as HKU1 and OC43.

VOC mutations in certain epitopes did not affect epitope-specific CD4+ T-cell recognition, while others diminished or abolished recognition. The epitopes with most mutations were present within the RBD region, the most common target of mutations in the VOCs.

Overall, data highlights the ultra-sensitivity of SARS-CoV-2 S-specific CD4+ T-cells to small amino acid (aa) changes in epitope sequences and the potential for epitope evasion through minor SARS-CoV-2 mutations.

Conclusions

The study data from T-cell clones and ex vivo PBMC experiments demonstrated variable effects of intra-epitope mutations on CD4+ T-cell recognition. Although the overall effect of point mutations was complex, triple aa deletions and multiple aa substitutions within individual epitopes greatly impacted CD4+ T-cell recognition.

The study also highlighted the significance of epitope mapping for rationalizing VOC risk stratification. Additionally, it emphasized the need for careful characterization of immunodominant CD4+ T-cell epitopes individually.

All HCW had antibody-based immunity against endemic beta-HCoVs, consistent with prior infection with these viruses, which indicated that T-cell clones were primed by SARS-CoV-2 infection. Importantly, broad CD4+ T-cell epitope targeted potentially limited evasion by current SARS-CoV-2 VOCs. Therefore, continual genomic surveillance efforts are warranted to help identify novel mutations conferring CD4+ T-cell immunity evasion capabilities to VOCs.

*Important notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Keeping it close: The role of a Campus COVID Support Team (CCST) in sustaining a safe and healthy university campus during COVID-19. Image Credit: Roman Babakin / Shutterstock

How a COVID support team mitigated SARS-CoV-2 transmission within a university community

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* pre-print server, researchers demonstrated how a campus coronavirus disease support team ...

Study: A Quantum Dot Biomimetic for SARS-CoV-2 to Interrogate Dysregulation of the Neurovascular Unit Relevant to Brain Inflammation. Image Credit: Yurchanka Siarhei/Shutterstock

Quantum dot biomimetic for SARS-CoV-2 examines neurovascular dysregulation related to brain inflammation

by Medical Finance
May 24, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-like...

Study: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age. Image Credit: Zouls/Shutterstock

Study explores SARS-CoV-2 antibody responses in mild COVID-19 cases

by Medical Finance
May 24, 2022
0

In a recent study posted to medRxiv* preprint server, researchers evaluated antibody responses in mild cases of coronavirus disease 2019...

Study: SARS-CoV-2 spike variants differ in their allosteric response to linoleic acid. Image Credit: Naeblys/Shutterstock

The response of four SARS-CoV-2 spike variants to linoleic acid removal

by Medical Finance
May 24, 2022
0

A recent paper posted to the bioRxiv* preprint server depicted the differential allosteric response of the severe acute respiratory syndrome coronavirus...

Study: Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces robust neutralizing salivary IgA. Image Credit: ustas7777777 / Shutterstock.com

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

by Medical Finance
May 23, 2022
0

The ability of the immune system to prevent the replication and subsequent transmission of pathogens is referred to as ‘sterilizing...

Study: Response to COVID-19 booster vaccinations in seronegative people with MS. Image Credit: Teeradej / Shutterstock.com

Response to COVID-19 boosters in seronegative multiple sclerosis patients

by Medical Finance
May 23, 2022
0

As of March 21, 2022, the coronavirus 2019 (COVID-19) has claimed the lives of almost 6.1 million globally. Vaccines have played...

Next Post
Study: Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. Image Credit: NIAID

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: STDs increased during the first year of the COVID-19 pandemic. Image Credit: BlurryMe/Shutterstock
    CDC report shows a continual surge in sexually transmitted diseases in US in 2020
  • Study: Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2. Image Credit: CROCOTHERY/Shutterstock
    Investigating extensive SARS-CoV-2 neutralizing immunoglobulins from COVID-19 recovered subjects
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply